ClinicalTrials.gg
Not yet recruitingNCT06819852Updated Nov 18, 2026

Acute Hospital Care at Home for People Living With Dementia

An interventional study of Acute hospital care at home and Standard medical treatment in Emergency Department Visit, Home Care Services and Dementia, sponsored by Brigham and Women's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,051 studies in Dementia with a site in United States — 211 open to participants now, 276 under way, 15 of them phase 3. Dementia · United States.

Planned enrollment
266th of 846
200 · median 93
Started
2026
with 64 others
No phase
562 of 1,051
118 open now
Primary completion
2029-07
later than 238 of 275 live
Registered
937th of 1,051
by date

Among the 1,051 studies in Dementia with a site in United States, this one is the 266th largest by planned enrollment of the 846 interventional ones that give a count, is one of 65 that started in 2026, is one of 562 with no phase, reaches primary completion later than 238 of the 275 other live ones, and was the 937th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

211 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,051 studies in Dementia with a site in United States, or all of them as a file.
02

Study summary

The investigators will perform a parallel-group multicenter randomized controlled trial of a 1-year pre-enrolled acute hospital care at home intervention vs usual care for people living with dementia. Patients will be randomized only after eligibility determination and after the family caregiver agrees to enroll; people living with dementia will assent when able. Patients will be allocated in a concealed fashion to the control and intervention groups in randomly selected block sizes of 4 or 6 in 4 strata reflecting their functional status (activities of daily living: 0, 1, 2-3, 4-6). Although family and clinicians cannot be blinded, the investigators will blind the data collectors and assessors.

03

Conditions studied

  • Emergency Department Visit
  • Home Care Services
  • Dementia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of moderate or severe dementia (as ascertained by the Quick Dementia Rating System; QDRS)
  • Resides in a private or assisted living residence with or nearby (\<15min travel time) to a family caregiver
  • Resides within the Mass General Brigham (MGB) home hospital catchment area
  • Has had at least 1 hospitalization in the last 12 months.

Exclusion criteria

Exclusion Criteria:

  • Hospitalized in the last 30 days
  • No functioning utilities, such as no working heat (October-April), no running water, or no electricity.
  • Resides in skilled nursing facility
  • Resides in group home
  • Domestic violence screen positive
  • In police custody
  • Family caregiver unable to initiate or maintain communication with care team
  • End-stage renal disease on hemodialysis
  • On methadone requiring daily pickup of medication
  • Active substance use disorder, without functioning treatment plan
  • Psychiatric diagnosis that would prohibit successful home hospital care
  • Acute delirium without explanation or without the ability to manage at home
  • Patients with cancer requiring consistent hospital-based treatments
  • Cannot ambulate to bedside commode with assistance present in the home (if different from baseline), unless home-based aides are available
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Usual care

    Acute care at a brick-and-mortar hospital.

    Other: Standard medical treatment

  • Experimental
    Acute hospital care at home

    Home visit for a serious illness conversation. Acute illness evaluation on demand. Acute hospital care at home as needed.

    Other: Acute hospital care at home

Interventions

  • OtherAcute hospital care at home

    Home visit for a serious illness conversation. Acute illness evaluation on demand. Acute hospital care at home as needed.

  • OtherStandard medical treatment

    Standard acute and emergency care delivered in a brick-and-mortar hospital setting.

06

What researchers measure

Primary outcomes

  1. Number of days at home

    Sum of the number of days spent at home within the 30-days after an acute care episode

    Time frame: Discharge to 30-days post discharge, up to 30 days

Secondary outcomes

  1. 30-day unplanned readmission or mortality

    Percentage of unplanned readmissions or mortality

    Time frame: Discharge to 30-days post discharge, up to 30 days

  2. Delirium

    Percentage of days experiencing delirium while receiving acute care using the short confusion assessment method.

    Time frame: Date of admission to date of discharge, estimated 5 days

  3. Health-related quality of life

    Absolute change of health-related quality of life over the year through the dementia quality of life survey (DEMQOL), or for patients unable to complete the survey, its proxy version (DEMQOL-Proxy).

    Time frame: From enrollment for the period of one year

  4. Physical activity

    Percent of time sedentary as measured by patch monitoring system.

    Time frame: Date of admission to date of discharge, estimated 5 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2029, 31 months later.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 31 months is above that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, last on Nov 18, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Apr 2029 → Jul 2029, on Oct 16, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2029 → Jul 2029, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 11, 2025
StartEst.
Dec 1, 2026was Aug 2026
Primary completionEst.
Jul 1, 2029was Apr 2029
CompletionEst.
Jul 1, 2029was Apr 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 17, 2026→Dec 1, 2026
moved 2 times, Oct 16, 2026 – Nov 18, 2026
Primary completion
Apr 1, 2029→Jul 1, 2029
Oct 16, 2026
Study completion
Apr 1, 2029→Jul 1, 2029
Oct 16, 2026
Show all 2 updates
  1. Nov 18, 2026
    Start date Nov 17, 2026→Dec 1, 2026
  2. Oct 16, 2026
    Start date Aug 17, 2026→Nov 17, 2026
    Primary completion Apr 1, 2029→Jul 1, 2029
    Study completion Apr 1, 2029→Jul 1, 2029

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06819852
Responsible party
David Levine (Associate Physician, Brigham and Women's Hospital) — Principal investigator
First posted
Feb 11, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

David M Levine, MD, MPH, MA
Contact
dmlevine@bwh.harvard.edu
617-732-7063
Fernando Chavarria, MD, MSc
Contact
fchavarria@bwh.harvard.edu
857-307-2673

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion